Ratio collects $70M for its radiopharmaceutical trials; Vogenx plans $67M IPO
Ratio Therapeutics raises $70M for radiopharma trials: The Boston biotech said the Series C funding came from existing investors Duquesne Family Office and Bristol Myers Squibb, as well as new ones ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.